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ABSTRACT:
Selenium compounds are known as cancer preventive agents and are also able to 
ameliorate the toxicity associated with anti-cancer radiation and chemotherapy in 
mouse models. Sensitivity to the toxicity of chemotherapy is also modulated by the 
circadian clock, molecular time-keeping system that underlie daily fluctuations in 
multiple physiological and biochemical processes. Here we show that these two 
mechanisms are interconnected. By screening a library of small molecules in a cell-
based reporter system, we identified L-methyl-selenocysteine as a positive regulator 
of the core clock protein, BMAL1. L-methyl-selenocysteine up-regulates BMAL1 at the 
transcriptional level both in cultured cells and in mice. We also show that in tissue 
culture selenium exerts its action by interfering with TIEG1-mediated repression 
of Bmal1 promoter. Selenium treatment fails to protect BMAL1-deficient mice from 
toxicity induced by the chemotherapeutic agent cyclophosphamide but does protect 
Clock mutant mice deficient in circadian rhythm control but having normal BMAL1. 
These findings define selenium as circadian modulator and indicate that the tissue 
protective effect of selenium results, at least in part, from up-regulation of BMAL1 
expression and subsequent enhancement of CLOCK/BMAL1-mediated transcription.
INTRODUCTION
Selenium is an essential trace element of fundamental 
importance to human health due to its anti-oxidant, anti-
inflammatory and anti-viral activities [1]. Various forms 
of  selenium  (both  organic  and  inorganic)  have  been 
shown to have chemopreventive effects in a variety of 
malignancies, including breast and prostate cancer [2, 3]. 
An organic form of selenium, L-methyl-selenocysteine 
(MSC), acts as a selective modulator of the therapeutic 
efficacy and systemic toxicity of anticancer drugs in a 
variety of human tumor xenograft models [4-6]. 
The molecular mechanisms of selenium action have 
been extensively investigated and multiple mechanisms 
have  been  proposed,  suggesting  that  the  biological 
effects of this compound are likely highly pleiotropic. 
Traditionally,  many  aspects  of  selenium  action  have 
been attributed to its anti-oxidant activity. In the form of 
selenocysteine, it is incorporated into several anti-oxidant 
enzymes, such as glutathione peroxidases and thioredoxin 
reductases, which are important for regulating the balance 
of  reactive  oxygen  species  (ROS)  in  an  organism  [7]. 
More recently, several aspects of selenium action have 
been  linked  to  both  positive  and  negative  regulation 
of  transcription  factors  that  are  involved  in  control  of 
normal cellular proliferation and cellular responses to Oncotarget 2011; 2:   1279 - 1290 1280 www.impactjournals.com/oncotarget
stress conditions, such as NFκB, Sp1 and Sp3 [8], HIF-
1α [4] and p53 [9]. Taken together, these data imply that 
selenium may modulate various pathways and that this 
regulation is likely to be tissue-specific. 
Many  aspects  of  mammalian  physiology  are 
controlled by the activity of components of the circadian 
clock  (reviewed  in  [10]. This  evolutionarily  conserved 
system  is  comprised  of  a  network  of  transcriptional 
and translational feedback loops that drive 24-hr-based 
oscillations in RNA and protein abundance of key clock 
components [11, 12]. This, in turn, translates into 24-hr 
periodicity in expression of a large number of output genes 
[13]. The molecular mechanism of circadian oscillation is 
operative in virtually all mammalian tissues and thereby 
influences a wide range of physiological and metabolic 
processes in a tissue-specific manner [14]. 
One of the important processes that are modulated 
by  the  circadian  clock  is  an  organism’s  response  to 
genotoxic stress, such as that induced by anticancer drug 
and  radiation  treatments.  Previously,  using  circadian 
mice deficient in different components of the circadian 
clock, we established a molecular link between the 
functional status of the major circadian CLOCK/BMAL1 
transcriptional  complex  and  the  sensitivity  of  normal 
tissues to toxicity induced by the chemotherapeutic agent 
cyclophosphamide (CY) [15]. These data, together with 
our  more  recent  work  [16,  17],  allowed  us  to  define 
circadian transcriptional activators as potential targets for 
pharmacological modulation aimed at protecting normal 
tissues from damage induced by genotoxic treatments. 
Here we report that selenium up-regulates the core 
circadian  protein,  BMAL1,  by  relieving  the  GC-box/
TIEG1-mediated  repression  of  Bmal1 promoter The in 
vivo effect of selenium was found to be tissue-specific in 
that selenium-induced changes in BMAL1 were detected 
in the liver, but not in the suprachiasmatic nucleus (SCN), 
the central pacemaker of the circadian system. Consistent 
with  this  tissue-specificity,  systemic  administration  of 
selenium did not affect circadian behavioral parameters; 
however, it did result in a significant increase in animals’ 
resistance  to  toxicity  induced  by  the  chemotherapeutic 
agent,  cyclophosphamide.  These  data  reveal  novel 
mechanisms of selenium action that are linked to 
regulation of the core clock components. 
RESULTS
A cell-based readout system reveals selenium 
compound as a circadian clock modulator 
Our  previous  studies  identified  CLOCK/BMAL1 
transcriptional  activity  as  a  target  for  pharmacological 
intervention  to,  among  other  potential  applications, 
reduce the toxicity associated with genotoxic anti-cancer 
treatments  [16].  To  identify  small  molecules  capable 
of  modulating  CLOCK/BMAL1  activity,  we  designed 
a  readout  system  based  on  mouse  fibrosarcoma  L929 
cells expressing high levels of endogenous CLOCK and 
BMAL1,  positive  regulators  circadian  transcriptional 
machinery,  transduced  with  Per1-driven  luciferase 
reporter  construct  (L929-Per1)  [18].  By  screening  a 
chemical  library  of  known  pharmacological  agents 
(LOPAC, Sigma, 1280 compounds total) in this system, 
we  identified  14  inhibitors  and  17  activators  of  Per1 
promoter as our major hits (Supplementary Tables 1 and 
Figure 1: Selenium specifically activates circadian promoter in a time and dose-dependent manner. (A). Selenium 
activates Per1 promoter in a dose-dependent manner. L929 cells carrying luciferase reporter genes under the control of either mPer1 or 
CMV promoters were treated with the indicated concentrations of MSA for 18 hrs. Luciferase activity was measured in cell lysates and 
normalized for β-Gal expression. The experiment was performed in triplicate; the values presented are mean fold-change relative to that in 
untreated cells ± standard error. (B). Selenium activates Per1 promoter in a time-dependent manner. L929-Per1-Luc cells were treated with 
different concentrations of MSA (0, 2, 5µM). Cells were collected at various time points over a period of 36 hrs and luciferase activity was 
measured. (C) L929-Per1-Luc cells were pretreated with different concentrations of MSA (0, 2, 5µM) for 18 hrs. MSA was then washed out 
and cells were collected at various time points over a period of 24 hr for measurement of luciferase activity. Values are mean from triplicates 
with error bars indicating standard deviation. 
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2). 
Among our primary hits, there were several known 
regulators of circadian function such as glucocorticoids 
[19], 2-methoxyestradiol [20], forskolin [21], PKC and p38 
MAPK inhibitors [22, 23], which validated the feasibility 
of our screening approach. Other compounds from this 
list, however, have not been previously linked to circadian 
function. Thus, among the chemicals identified as potent 
upregulators of Per1 promoter we were intrigued to find 
an organic selenium compound, L-methyl selenocysteine 
(MSC).  Subsequent  experiments  using  methylseleninic 
acid (MSA, a form of MSC optimized for in vitro studies) 
showed  that  treatment  with  MSA  specifically  induced 
an increase in Per1-driven luciferase activity in a dose-
dependent  manner  (Fig.  1A). A  significant  increase  in 
reporter signal can be detected as early as 6 hrs after MSA 
treatment reaching its maximum at 18 hrs post incubation 
(Fig. 1B). This promoter induction is reversible, as after 
removal  of  MSA,  activity  of  Per1-driven  luciferase 
remained high for ~6 hrs, after which it returned to its 
basal level within ~ 24 hrs (Fig. 1C). 
The rapid kinetics of induction of luciferase activity 
Figure 2: Selenium-dependent up-regulation of the Per1 promoter is mediated through BMAL1. (A) Treatment with 
selenium results in acute induction of the Bmal1 promoter. 293T cells were transfected with indicated reporters; 24hrs after transfection 
cells were treated with 5uM MSA for 6 hrs and luciferase activity was measured in cell lysates. Values represent mean from triplicates 
with error bars indicating standard deviation. (B) Treatment with selenium results in an increase of endogenous Bmal1 mRNA. L929 cells 
were treated with 5uM of MSA for indicated times. The relative abundance of Bmal1 mRNA was determined by real-time RT-PCR using 
the comparative delta Ct method. The final measurements were normalized based on Gapdh mRNA expression and are shown as the fold-
change. (C) Selenium increases the abundance of BMAL1 protein. L929 cells were treated with 5uM of MSA for indicated times. The 
abundance of BMAL1 and PER1 in whole cell extracts was analyzed by Western blot (top panel). Two individual samples for each time 
point are shown. Lower panel presents quantitative analysis of BMAL1 and PER1 expression showing an increase in BMAL1 in 4hrs after 
MSA treatment followed by an increase in PER1. (D) Suppression of BMAL1 by specific siRNA abrogates selenium-mediated increase in 
Per1 activation. L929 cells containing the Per1-Luc construct were transfected with siRNA against BMAL1 or control non-targeting (-) 
siRNA. 72hrs post-transfection, cells were treated with 5μM MSA and luciferase activity was measured in cell lysates. The values represent 
mean ± standard deviation. 
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by MSA suggested that selenium may exert its effect at the 
level of transcriptional activation. To determine which of 
the clock genes could be targeted by selenium, we tested 
the affect of MSA on basal promoter activity of Clock, 
Bmal1,  Per1,  Per2 and Cry1 genes using a luciferase 
reporter  assay.  Of  all  the  promoters  tested,  only  Per1 
and Bmal1 were up-regulated by MSA, with the Bmal1 
promoter showing the highest fold of activation (Fig. 2A). 
MSA-induced  activation  of  Bmal1 gene transcription 
was  confirmed  by  measuring  levels  of  corresponding 
endogenous  Bmal1  mRNA  in  L929  cells  at  different 
times after MSA treatment (Fig. 2B). The peak time of 
RNA  expression  (4  hrs  after  incubation  with  MSA)  is 
tightly  coupled  with  increase  in  BMAL1  protein  (Fig. 
2C), whereas kinetics of modest increase in PER1 protein 
suggests that it is dependent on the activation of BMAL1 
(Fig. 2C). Consistent with this, suppression of BMAL1 
by  specific  siRNA  completely  blocked  the  stimulatory 
effect  of  MSA  on  CLOCK/BMAL1-driven  activation 
of the Per1 promoter (Fig.2D). The abundance of other 
clock transcripts and proteins including CLOCK, PER2, 
CRY1  and  CRY2  was  not  affected  by  MSA  (data  not 
shown). Together, these data suggest that MSA-induced 
activation of the Per1 promoter results from up-regulating 
the Bmal1 gene followed by an increase in abundance and 
presumably activity of the corresponding protein.
The effects of selenium on BMAL1 are mediated 
through transcriptional repressor TIEG1
Since our results in tissue culture demonstrated 
that  MSA  activates  the  Bmal1 promoter, we sought to 
determine the region important for this regulation. It has 
been previously reported, that Bmal1 is regulated by two 
transcription factors REV-ERBα (transcription repressor) 
and  RORα  (transcription  activator)  competing  for  the 
same RORE element in its promoter region [24-27]. More 
recently, the glucose-inducible gene Tieg1, which encodes 
an Sp1 family transcription repressor, was identified as 
another important regulator of Bmal1 transcription. The 
Sp1 and Sp1-like transcription factors have been linked 
Figure 3: Selenium mediates Bmal1 upregulation through TIEG1 repressor binding sites. (A) Nucleotide sequence of 
the putative core promoter of the mBmal1 gene.  The transcription start site of ORF is designated +1. Potential TIEG1 binding sites are 
underlined. The Bmal1 promoter fragments used (Bmal1-61 and Bmal1-17) are indicated by bold number above the truncation sites (-17 and 
-61). (B). Selenium up-regulates Bmal1 promoters that contain the most proximal TIEG1 binding-sites. 293T cells were transfected with 
one of three Bmal1 promoter fragmented reporter genes (816bp, 61bp, or 17bp upstream from +1bp transcription start site). 18hour post 
transfection cells were treated with or without indicated concentrations of selenium (MSA) and harvested 9 hours later to be analyzed for 
luciferase expression. (C). Selenium-mediated up-regulation of Bmal1 gene is compromised in a promoter lacking the two most proximal 
TIEG1 sites. Bmal1-816 was used as a template to generate a promoter lacking the two proximal TIEG1-sites, which were previously 
determined to be responsible for Bmal1 gene repression [32]. The primer used in the site-directed mutagenesis is shown below the two 
TIEG1 proximal sites, and the specific mutated base pairs are shown in red. Cells were transfected with either wild-type Bmal1-816 reporter 
gene (black bars) or TIEG1 binding site mutant Bmal1-816 (gray bars) and treated without or with MSA at 5 and 10uM.
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Figure 4: Selenium up-regulates Bmal1 expression in mouse liver. (A) Selenium administration results in acute induction of 
Bmal1 transcript in mouse liver. C57BL/6J mice received singe i.p. injection of MSC (10mg/kg) or PBS at ZT03 (zeitgeber time, ZT00 
corresponds to the time of lights on). Livers were collected 1 and 3 hrs later (ZT04 and ZT06 respectively), and relative abundance of 
Bmal1 mRNA was measured by real-time RT-PCR or PBS at ZT03 (zeitgeber time, ZT00 corresponds to the time of lights on). Data present 
mean values for three mice ± standard deviation. (B) Selenium-induced activation of the Bmal1 promoter results in increase in BMAL1 
protein in liver. Western blot analysis of total lysates of liver obtained from the same animals as in (A). (C-F) Selenium increases BMAL1 
protein in liver when administered by oral gavage. Western blots (C,E) and their quantitative analysis (D,F). Twenty animals received either 
PBS or MSC (7.5 mg/kg, oral gavage) daily for two weeks. Tissue samples were collected on day 15 at either ZT04 (C,D) or ZT10 (E,F) 
and probed with anti-BMAL1 antibody. Each lane represents tissue lysate obtained from an individual animal. Actin was used to control 
for loading. ImageQuant software was used for Western blots quantitation. Cell lysates from L929 and 293T cells were used as positive 
controls for endogenous and ectopically expressed BMAL1 respectively. (G) Selenium has no effect on BMAL1 expression in the SCN. 
Animals were fed daily with either PBS or MSC (7.5 mg/kg, oral gavage) for two weeks. Animals were then sacrificed for preparation 
of SCN tissue sections. The 12 μm sections were stained with anti-BMAL1 antibody followed by staining with a fluorescently-labeled 
secondary antibody (red). DAPI (blue) was used to stain the nuclei of all cells. SCN sections obtained from untreated Bmal1-/- mice are 
shown as controls for specificity of the antibody. Consistent with previous reports [52], no daily variations in BMAL1 immuno-reactivity 
were detected. Representative sections of the brains collected at ZT02 are shown. (H) The abundance of BMAL1 protein in mouse livers 
correlates with the amount of selenium in their diets. Animals were fed regular (Reg), selenium-free (SF) or selenium-enriched (SR) diets 
for 6 weeks. Tissue samples were collected at ZT10 and used for Western blotting with anti-BMAL1 antibody. Each lane represents tissue 
lysate obtained from an individual animal. (I) Quantitation of the Western blot (G) using ImageQuant software. Expression of BMAL1 
was normalized based on ACTIN levels. Values represent mean ± standard error, n=3/group. *p=0.06; **p=0.007 (Student’s t-test). (J) 
Selenium-induced changes in the level of BMAL1 correlate with increased level of its direct transcriptional target Per1 in the liver. Same 
animals as in G were used. Relative mRNA abundance was determined by real-time RT-PCR using the comparative delta Ct method. The 
final measurements were normalized by Gapdh mRNA expression. Values represent mean ± standard deviation, n=3/group. *p=0.04; 
**p=0.01 (Student’s t-test). 
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to the regulation of several genes by selenium [28-30]. 
The mechanism of selenium regulation has not been 
elucidated,  but  is  likely  to  involve  regulation  of  zinc-
finger  DNA  binding.  Previous  analysis  of  the  Bmal1 
promoter  revealed  three  potential  Sp1  binding  sites  in 
proximity  to  the  transcription  initiation  site  [31];  and 
of these three sites, the two most proximal Sp1-binding 
sites were shown to bind TIEG1 and repress Bmal1 gene 
promoter [32](Fig. 3A). To test whether selenium might 
inhibit TIEG1 binding to these proximal Sp1-binding sites, 
truncated Bmal1 promoters that included the two most 
proximal  TIEG1-binding  sites  (Bmal1-816  and  Bmal1-
61) and one that excluded TIEG-binding site (Bmal1-17) 
were used in a luciferase transcription assay. MSA was 
shown to upregulate Bmal1 promoters that included the 
proximal TIEG1-sites and MSA effect was ablated with 
a Bmal1 promoter lacking the proximal TIEG1 sites (Fig. 
3B). To further confirm the importance of the proximal 
TIEG1 repressor binding sites in MSA effect on Bmal1 
expression, the Bmal1-816 plasmid construct was used 
as a template in site-directed mutagenesis to generate 
specific  point  mutations  of  the  proximal  TIEG1  sites 
using  the  primer  depicted  in  Figure  3A.  The  Bmal1 
promoter  lacking  the  two  most  proximal  TIEG1  sites 
was  compromised  for  MSA-induction  (Fig.  3C).  We 
next asked whether the circadian regulated TIEG1 might 
overcome the upregulation of Bmal1 promoter by MSA. 
Cells were co-transfected with Bmal1-816bp  reporter 
gene and empty vector or increasing amounts of TIEG1 
expression plasmid. The transcriptional luciferase results 
clearly show that high levels of ectopic TIEG1 represses 
Bmal1 expression even in the presence of MSA (Fig. 3D). 
These data suggest that selenium mediates its effects on 
Bmal1 expression at least in part through the two most 
proximal TIEG1 elements. 
Selenium administration increases the abundance 
of the BMAL1 protein in vivo
To test whether selenium has a similar stimulatory 
effect and kinetics on BMAL1 protein in vivo as observed 
in culture, we administered it in the form of MSC to mice 
as a single i.p. injection (10 mg/kg). The injection was 
performed at ZT03, when Bmal1 expression is normally 
at its lower daily levels and livers were collected 1hr and 
3hrs post injection. Similar to our results obtained in tissue 
culture,  selenium  administration  caused  a  significant 
increase in Bmal1 RNA (Fig. 4A) and protein (Fig. 4B). 
Next, we tested whether this increase could be induced 
by prolonged systemic administration of selenium. For 
this, we administered MSC via gavage daily for a period 
of 2 weeks, and measured levels of BMAL1 protein in 
two tissues: the liver, which is the major metabolic tissue 
with prominent circadian regulation, and in neurons of the 
SCN, the site of the mammalian master clock. To account 
for normal circadian variations in BMAL1 levels in the 
liver, tissue samples were collected at two time points, 
ZT04 and ZT10. Similar to acute induction in response to 
a single administration, systemic administration caused a 
significant increase in BMAL1 protein levels in the liver 
at both times tested (Fig. 4C-F). At the same time, despite 
the ability of selenium to cross the blood-brain barrier 
[33],  no  increase  in  BMAL1  immunoreactivity  was 
detected in the SCN of animals fed with MSC compared 
to animals fed with PBS (Fig. 4G) independent of time of 
brain collection. 
The BMAL1 abundance in the liver directly correlated 
with the amount of selenium when it was administered 
as a dietary supplement in the form of sodium selenite 
(Fig. 4H,I). These diet-associated differences correlated 
with the levels of Per1 mRNA expression measured at 
its normal peak time at ZT10 (Fig. 4J). Consistent with 
the lack of selenium effect on the abundance of BMAL1 
in  the  SCN,  circadian  behavioral  parameters  were  not 
affected by the type of diet (Fig. S1, Table S3). These 
data suggest that selenium affects the level and activity 
of BMAL1 in a tissue-specific manner and that selenium-
mediated regulation of BMAL1 may play an important 
physiological role in liver-specific processes. 
Selenium treatment ameliorates toxicity induced 
by the chemotherapeutic agent cyclophosphamide 
in vivo
Previously,  we  showed  that  sensitivity  to  the 
chemotherapeutic drug CY is modulated by the functional 
status  of  the  CLOCK/BMAL1  transcriptional  complex 
and that animals deficient in positive components of the 
molecular clock (Clock mutant and Bmal1-/- knockout 
mice) demonstrated enhanced sensitivity to CY-induced 
toxicity [15]. These data, together with the known ability 
of selenium to reduce chemotherapy-associated toxicity 
and  our  finding  that  selenium  can  modulate  CLOCK/
BMAL1 activity via up-regulation of BMAL1, prompted 
us  to  test  whether  selenium  could  rescue  CY-sensitive 
circadian  mutant  mice  from  drug-induced  toxicity.  To 
test this hypothesis, we administered MSC to wild type, 
Clock/Clock mutant and Bmal1-/- knockout mice that 
received CY according to a previously described schedule 
[5,  15].  As  expected,  Clock/Clock and Bmal1-/- mice 
were significantly more sensitive to CY-induced toxicity 
manifested by severe hematopoietic syndrome. Selenium 
administration alleviated CY-induced toxicity in Clock/
Clock mice, bringing both the survival rate (Fig. 5A) and 
number  of  circulating  lymphocytes  (Fig.  5B)  to  levels 
comparable to those of wild type animals. The rescuing 
effect  correlated  with  an  increase  in  BMAL1  protein 
levels in the livers of Clock mutant mice (Fig. 5D). In 
contrast, mice with genetic disruption of the Bmal1 gene 
were non-responsive to rescuing effect of selenium as both Oncotarget 2011; 2:   1279 - 1290 1285 www.impactjournals.com/oncotarget
control and MSC-treated Bmal1-/- mice showed similar 
kinetics of mortality and loss of circulating lymphocytes 
following  the  CY  exposure  (Fig.  5A,C)  These  data 
confirm that the rescuing effect of selenium in vivo is 
mediated, to a large extend, through BMAL1. The ability 
of  selenium  to  increase  CLOCK/BMAL1-dependent 
transactivation even when BMAL1 forms a complex with 
the  mutant  CLOCK  protein  expressed  in  Clock/Clock 
mice (CLOCK-Δ19) [34] was confirmed in cultured cells 
expressing ectopic BMAL1 and CLOCK-Δ19 (Fig. 5E). 
Figure 5: Selenium rescues cyclophosphamide-sensitive Clock mutant mice from drug-induced toxicity. (A) Kaplan-
Meyer survival curves. Wild type (WT), Clock mutant and Bmal1-/- mice were given either PBS (blue) or MSC (red, 7.5 mg/kg) daily for 2 
weeks and injected with CY, 3x150mg/kg. Grey arrows in the Kaplan-Meyer plot indicate days of PBS or MSC administration; red arrows 
indicate days of CY injection. Treatment with MSC dramatically increased the 25-day survival rate of CY-treated Clock/Clock mice but had 
no effect on survival of Bmal1 knockout animals. The experiment was performed three times with similar results. (B) Selenium treatment 
decreases CY-induced neutropenia and leukocytopenia. Total white blood cells (WBC), neutrophils (Neut) and lymphocyte (Lymph) counts 
in peripheral blood of wild type and Clock mutant mice treated with PBS or MSC and CY as described for Fig. 5A. MSC-induced increase 
in survival of CY-treated Clock mutant mice correlates with significant increase in the number of circulating lymphocytes (Student’s t-test 
p=0.015, n=5/group). (C) Selenium has no effect on the number of circulating lymphocytes in CY-treated Bmal1-/- mice. Mice were treated 
with PBS or MSC and CY as described in Fig. 5A. The cell count data are mean values for 8 mice. Please note that absolute values cannot 
be directly compared between the Clock/Clock (Fig. 4A) and Bmal1-/- mice since the experiments were not performed simultaneously. (D) 
Selenium administration increases BMAL1 protein abundance in the livers of Clock/Clock mice. Western blot analysis of liver extracts of 
five individual Clock/Clock mice fed with either PBS or MSC with anti-BMAL1 and anti-CLOCK antibodies. No effect on CLOCK-∆19 
expression level was detected. (E) Selenium increases CLOCK-Δ19/BMAL1-mediated activation of a responsive promoter. HEK293T 
cells were transfected with Per1-Luciferase reporter, HA-BMAL1 and either full-length wild type CLOCK or deletion mutant CLOCK 
(CLOCK-Δ19) and treated with indicated concentrations of MSA. Luciferase activity of cell lysates was normalized with β-Gal. Bars 
represent mean values ± standard error. Asterisk indicate statistically significant increase in promoter activation; *p=0.0011, **p=0.0012 
(Student’s t-test). 
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Together, these results suggest that selenium ameliorates 
CY-induced toxicity via its stimulatory effect on BMAL1 
resulting  in  upregulation  of  CLOCK/BMAL1-mediated 
expression of target genes critical for survival/recovery of 
hematopoietic cells in the face of genotoxic stress. 
DISCUSSION
Cancer  treatment  involves  frequent  use  of  highly 
toxic compounds that commonly induce severe adverse 
effects  reducing  efficacy  of  therapy,  creating  risks  of 
acquisition  of  additional  diseases  and  reducing  quality 
of life of cancer patients. That is why development of 
new  therapeutic  approaches  allowing  overcoming  side 
effects of chemotherapy and radiation is highly desirable. 
In this respect, the components of the molecular clock 
are  attractive  therapeutic  targets:  they  are  ubiquitously 
expressed  in  virtually  all  tissues  including  those  that 
determine  an  organism’s  sensitivity  to  genotoxic 
treatments and more experimental evidence suggest that 
key circadian proteins can directly or indirectly modulate 
stress response pathways [17]. 
High-throughput  screening  of  libraries  of  small 
organic molecules is one of the main tools for the discovery 
of bioactive compounds. This approach was successfully 
used recently to identify chemical compounds affecting 
basic circadian parameters (circadian period, amplitude 
and phase of rhythmicity) in circadian-synchronized cells 
[35, 36]. We reached similar goals using non-synchronized 
readout  system  that  enabled  selection  of  compounds 
modulating  average  level  of  activity  of  circadian 
transcriptional  machinery  revealed  by  the  expression 
of  the  reporter  driven  by  CLOCK/BMAL1-dependent 
circadian  promoter.  To  our  surprise,  this  screening 
approach identifies organic selenium compounds as potent 
up-regulators of Per1 promoter. 
Selenium is an essential trace element that has 
two  major  clinical  applications:  tumor  prevention  and 
protection against DNA damage induced by anti-cancer 
therapy. Studies in cell-based model systems as well as 
several  clinical  trials  have  conclusively  demonstrated 
that selenium supplementation ameliorates radiation-
induced mucositis in mice treated with fractionated doses 
of  ionizing  radiation  [37]  as  well  as  radiation-induced 
diarrhea in treatment of patients with cervical and uterine 
cancers [38]. Our findings provide a plausible mechanism 
behind tissue protective effects of selenium by linking 
it to circadian regulation of gene expression. This study 
suggests that selenium is capable of tuning circadian 
transcriptional machinery to the higher activity associated 
with  maximum  resistance  by  upregulating  BMAL1 
expression. 
Our data, as well as other reports [39, 40], show 
the  effect  of  selenium  to  be  highly  tissue-specific. 
Thus,  no  changes  in  BMAL1  levels  were  detected  in 
the  SCN;  accordingly,  selenium  administration  has  no 
effect on SCN-governed rhythms in locomotor activity. 
It is important to note that the lack of systemic effect of 
selenium on circadian rhythmicity presents an advantage 
from the therapeutic standpoint, as it allows for modulation 
of response to genotoxic treatments in a tissue-specific 
manner without disturbing the central clock. 
Tissue specificity of the observed effects may also 
be the underlying reason for the selectivity of selenium-
mediated protection for normal, as opposed to tumor, 
tissues. Testing of a large panel of tumor cell lines and 
animal tumor models would be needed to determine how 
universal the selectivity of BMAL1-mediated protective 
effects  towards  normal  tissues  is.  Quite  interestingly, 
recent  reports  demonstrated  that  in  mammary  gland, 
selenium administration induces upregulation of another 
circadian  protein,  PER2,  in  a  BMAL1-independent 
manner [39, 40] and that this upregulation may underlie 
tumor preventive properties of selenium compounds. Thus, 
both  cytoprotective  and  chemopreventive  functions  of 
selenium are likely to be exerted through the components 
of the molecular clock in a tissue-specific manner and 
presumably via different mechanisms. 
Additional work is needed to fully understand the 
mechanism, by which the increase in CLOCK/BMAL1 
activity  ameliorates  CY-induced  toxicity.  Our  previous 
work  has  suggested  that  CLOCK/BMAL1-dependent 
modulation of the lymphocyte survival/recovery rate is an 
important factor in determining the in vivo drug response 
and survival in clinical therapy [15]. Consistent with this, 
studies with Bmal1-/-  mice  revealed  the  involvement 
of BMAL1 in differentiation of pre-B to mature B cells 
although direct molecular targets are still not known [41]. 
Another  potential  mechanism  may  involve  BMAL1-
dependent  regulation  of  ROS  homeostasis  [42],  which 
would  protect  against  their  excessive  accumulation  in 
response  to  genotoxic  stress  and  thereby  ameliorate 
drug-induced  tissue  damage.  However,  regardless  of  a 
precise molecular mechanism, the reported here ability of 
selenium to modulate activity of circadian transcriptional 
complex without affecting central clock, opens new 
possibilities  for  clinical  applications.  If  previously  we 
considered  clock-targeting  pharmaceuticals  mostly  as 
resetting agents (with the goal to reset molecular clocks 
in  drug-  and  radiation-sensitive  tissues  to  times  of 
higher resistance to genotoxic treatment), now we have 
a compound capable of minimizing the damaging effects 
of  genotoxic  treatments  by  constant  up  regulation  of 
circadian  transcriptional  activators  in  a  tissue-specific 
manner. Since selenium is an essential trace element that 
is approved for clinical use it should be considered in 
clinical trials as chemo- and radiotherapy adjuvant. Oncotarget 2011; 2:   1279 - 1290 1287 www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Chemicals
Library  of  Pharmacologically  Active  Compounds 
(LOPAC),  cyclophosphamide  (CY)  and  Se-Methyl-
seleno-L-cysteine  (MSC)  were  purchased  from  Sigma. 
Methyl  seleninic  acid  (MSA)  was  purchased  from 
PharmaSe  Inc.  (Lubbock,  TX).  Actonomycin  D  was 
purchased from Denville (Metuchen, NJ). DyLight594-
conjugated  donkey  anti-Guinea  pig  IgG  antibody  was 
obtained  from  Jackson  ImmunoResearch  (West  Grove, 
PA). Prolong Gold Antifade reagent containing DAPI was 
purchased from Invitrogen (Carlsbad, CA).
Animals
Female Clock mutant mice [43-45] were backcrossed 
to  C57BL/6J  mice  for  19  generations.  Female  Bmal1 
-/-  mice  [46]  were  backcrossed  to  C57BL/6J  for  13 
generations. Animals of 8-10 weeks old were synchronized 
to a 12h light: 12h dark cycle (LD 12:12) for at least 2 
weeks before the experiment. Animals received selenium 
in the form of MSC either through a single i.p. injection 
at 10mg/kg or by gavage (once a day at ZT10) for 14 
days at 7.5mg/kg daily [5]. For long-term experiments, 
selenium was administered with selenium supplemented 
diet (Harlan TD.01652; 3ppm of selenium) in the form 
of  selenium  selenite.  Control  animals  received  either 
regular  (0.1ppm  of  selenium,  TD.96363)  or  selenium-
deficient  diet  (<0.01ppm;  TD.92163).  To  assess  acute 
effects of selenium on clock genes expression, tissue 
samples were collected 1 hr and 3 hrs after a single i.p. 
injection. In long-term experiments, tissue samples were 
collected  after  14-days  of  MSC  administration  at  two 
time points, ZT04 and ZT10. In all experiments tissue 
samples were immediately frozen in liquid nitrogen and 
stored at -800 C until RNA and protein extraction. When 
MSC administration was combined with CY treatment, 
intraperitoneal injections of CY (150 mg/kg) were done 
at days 8, 10 and 12 as described previously [15]. CY-
induced  toxicity  was  assessed  by  mortality  and  body 
weight loss. The loss of 20% of the original body weight 
was considered an endpoint of the experiment. All animal 
studies were conducted in accordance with the regulations 
of the Committee on Animal Care and Use at the Roswell 
Park Cancer Institute.
Plasmids and luciferase reporter constructs
Luciferase reporters containing the mPer1  [47], 
Bmal1  [31],  Cry1  [48]  and  Per2  promoters  [25]  have 
been  described  previously.  Tieg1-expressing construct 
is  described  in  [32].  HA-Bmal1,  HA-Clock,  and  HA-
ClockΔ19  are  described  in  [48].  A  specific  TIEG1 
binding site mutant of Bmal1 promoter was generated 
by  Site-directed  mutageneis  using  QuikChange  kit  as 
per  manufacturer’s  recommendations  (Stratagene,  Inc., 
LaJolla,  CA).  The  primer  oligonucleotides  used  were 
5’-CGATTGGTGttCGGGGttCCGGCCTG-3’  and 
its complement (lowercase italicized letter indicates 
substituted nucleotide).
Cell-based assay optimization and library 
screening
Screening conditions were optimized by testing the 
assay  for  temporal  and  spatial  signal  variability  using 
several  96-well  plates  as  described  in  [18].  Luciferase 
readings of untreated cells (constant high luciferase 
signal) and cells treated with Actinomycin D (background 
signal) were used to calculate Z-factor using the equation:
( )
c s
c s
Z
µ µ
δ δ
−
+
− =
3 3
1
 [49].   
Absence of spatial (edge effects) and temporal artifacts 
and Z-factor between 0.6 and 0.8 validated the assay. 
For screening, cells were plated onto the white 
clear-bottom 96-well tissue culture plates at 3x104/well 
in DMEM supplemented with 10% FBS without phenol-
red. JANUS automated liquid handling system (Perkin 
Elmer) equipped with pin tool (V&P Scientific, Inc) was 
used to deliver 100-120 nl of each of 1280 compounds 
present  in  LOPAC  library  to  the  96-well  assay  plates. 
Luciferase  activity  was  measured  in  24-30  hrs  after 
compound  delivery  using  Bright-Glo  Luciferase  assay 
system and GloMax luminometer (Promega) according 
to manufacture’s protocol. Every compound that either 
reduced or increased the luciferase signal by more than 
4  standard  deviations  was  selected  as  a  primary  hit. 
Primary hits that reduced the luciferase signal were tested 
for  general  toxicity  individually  using  CellTiter-Blue 
cell viability kit (Promega) according to manufacturer’s 
protocol. 
Transient transfection and luciferase reporter 
assay
HEK 293T cells were transiently transfected in 24-
well plates with plasmid DNA (the final DNA amount was 
adjusted to 300 ng with pcDNA3 vector) using FuGene 
reagents (Roche) according to the manufacturer’s protocol. 
10 ng of pcDNA3-βGal was included for normalization of 
transfection efficiency. Cells were collected for analysis 
30h after transfection. Luciferase activity was measured 
with Luciferase Assay System (Promega, Madison, WI) 
according to manufacturer’s protocol. βGal activity was Oncotarget 2011; 2:   1279 - 1290 1288 www.impactjournals.com/oncotarget
measured  with  2-nitrophenyl-β-D-galactopyranoside  as 
previously described [50].
RNA isolation and real-time PCR analysis
Total RNA was isolated from cultured cells using 
RNeasy  RNA  extraction  kit  (Qiagen).  Total  RNA  was 
isolated  from  livers  using  TRIZol  reagent  (Invitrogen) 
according to manufacturer’s protocol. TaqMan real-time 
RT-PCR  was  performed  using  the  following ABI  pre-
made primers/probes sets:
Clock: Mm00455950-m1
Bmal1: Mm00500226-m1
Per1: Mm00501813-m1
Per2: Mm00478113-m1
Cry1: Mm00514392-m1
Cry2: Mm00546062-m1
Reactions were run on 7500 real-time PCR system 
(Applied Biosystems) and relative mRNA abundance was 
calculated using the comparative delta-Ct method with 
Gapdh mRNA as a standard as previously described [13]. 
siRNA-mediated suppression of gene expression
Cells were seeded onto 24-well plates and transfected 
with siRNA against clock genes (siGENOME SMART 
pool, Dharmacon) according to manufacturer’s protocol. 
Reduction in protein levels was evaluated in tissue lysates 
collected 72 hrs post transfection by Western blotting with 
specific  antibody.  siGenome  non-targeting  siRNA  was 
used as a negative control and Cyclophillin B siRNA was 
used as a positive control for efficiency of transfection.
Western blot analysis and antibodies
Endogenous  CLOCK  and  BMAL1  were  detected 
with anti-CLOCK and anti-BMAL1 antibodies raised in 
guinea pig (Cocalico Biologicals, Inc., Reamstown, PA) 
according  to  the  protocol  described  in  [51]. Anti-actin 
antibody  was  purchased  from  Sigma  (St.Louis,  MO). 
HRP-conjugated  secondary  anti-rabbit,  anti-mouse  and 
anti-guinea pig antibodies were purchased form Jackson 
Laboratory.
Immunohistochemisty
  Deeply  anesthetized  animals  were  transcardially 
perfused  with  fixative  (4%  paraformaldehyde  in  PBS). 
Brains  were  removed  immediately  after  perfusion 
and postfixed for 2 h in the same fixative at 4°C. After 
washing in PBS, brains were placed in 30% sucrose in 
PBS for cryoprotection, embedded in NEG -50 medium 
(Richard-Allan Scientific, Whaltham, MA), and sectioned 
at  12  μm.  Coronal  sections  through  the  hypothalamus 
containing SCN were mounted on slides and processed 
for the immunohistochemical detection of BMAL protein 
using  a  standard  immunofluorescence  technique  using 
primary  antibody  against  BMAL1  at  1:100  dilution 
followed by secondary antibody staining (DyLight594-
conjugated donkey anti-guinea pig IgG antibody, Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) at 
1:400 dilution. Sections were mounted with Prolong Gold 
Antifade reagent containing DAPI (Invitrogen, Carlsbad, 
CA)  and  analyzed  with  Axio  Imager  Z1  microsocpe 
(Zeiss)  equipped  with  epifluorescence.  Images  were 
collected with Hamamatsu OTCA-R2 digital camera and 
AxioVision software.
Behavioral analysis
 Mice were singly housed in cages equipped with 
a running wheel at 12h light:12h dark cycle (LD12:12) 
for at least 2 weeks before being released into constant 
darkness (DD). Activity data were collected as previously 
described [43, 45]. The analyses were performed using 
ClockLab software (Actimetrics, Inc, Evanston, IL). 
Total Blood Cell Analysis
Hematological evaluation of blood composition was 
performed two days after the last CY injection. Peripheral 
blood obtained from the retroorbital sinus was collected 
into EDTA-treated tubes; the complete blood cells counts 
with WBC differentials were measured by using Advia 
120 hematology system (Bayer) and analyzed with the 
software  application  for  C57BL/6J  mice.  All  control 
parameters were within the range previously described for 
this mouse strain.
Statistical Analyses
 Statistic significance in mRNA and protein levels 
was evaluated with Student’s t-test. P values <0.05 were 
considered statistically significant.
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